Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism.

Foloppe J, Kempf J, Futin N, Kintz J, Cordier P, Pichon C, Findeli A, Vorburger F, Quemeneur E, Erbs P.

Mol Ther Oncolytics. 2019 Mar 27;14:1-14. doi: 10.1016/j.omto.2019.03.005. eCollection 2019 Sep 27.

2.

By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1.

Kleinpeter P, Remy-Ziller C, Winter E, Gantzer M, Nourtier V, Kempf J, Hortelano J, Schmitt D, Schultz H, Geist M, Brua C, Hoffmann C, Schlesinger Y, Villeval D, Thioudellet C, Erbs P, Foloppe J, Silvestre N, Fend L, Quemeneur E, Marchand JB.

J Virol. 2019 May 15;93(11). pii: e00207-19. doi: 10.1128/JVI.00207-19. Print 2019 Jun 1.

3.

Oncolytic properties of non-vaccinia poxviruses.

Ricordel M, Foloppe J, Pichon C, Findeli A, Tosch C, Cordier P, Cochin S, Quémeneur E, Camus-Bouclainville C, Bertagnoli S, Erbs P.

Oncotarget. 2018 Nov 13;9(89):35891-35906. doi: 10.18632/oncotarget.26288. eCollection 2018 Nov 13.

4.

Vaccinia Virus Shuffling: deVV5, a Novel Chimeric Poxvirus with Improved Oncolytic Potency.

Ricordel M, Foloppe J, Antoine D, Findeli A, Kempf J, Cordier P, Gerbaud A, Grellier B, Lusky M, Quemeneur E, Erbs P.

Cancers (Basel). 2018 Jul 10;10(7). pii: E231. doi: 10.3390/cancers10070231.

5.

Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells.

Delaunay T, Violland M, Boisgerault N, Dutoit S, Vignard V, Münz C, Gannage M, Dréno B, Vaivode K, Pjanova D, Labarrière N, Wang Y, Chiocca EA, Boeuf FL, Bell JC, Erbs P, Tangy F, Grégoire M, Fonteneau JF.

Oncoimmunology. 2017 Dec 26;7(3):e1407897. doi: 10.1080/2162402X.2017.1407897. eCollection 2018.

6.

Ultrasound-mediated cavitation does not decrease the activity of small molecule, antibody or viral-based medicines.

Myers R, Grundy M, Rowe C, Coviello CM, Bau L, Erbs P, Foloppe J, Balloul JM, Story C, Coussios CC, Carlisle R.

Int J Nanomedicine. 2018 Jan 10;13:337-349. doi: 10.2147/IJN.S141557. eCollection 2018.

7.

Cowpox Virus: A New and Armed Oncolytic Poxvirus.

Ricordel M, Foloppe J, Pichon C, Sfrontato N, Antoine D, Tosch C, Cochin S, Cordier P, Quemeneur E, Camus-Bouclainville C, Bertagnoli S, Erbs P.

Mol Ther Oncolytics. 2017 Aug 24;7:1-11. doi: 10.1016/j.omto.2017.08.003. eCollection 2017 Dec 15.

8.

Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition.

Kleinpeter P, Fend L, Thioudellet C, Geist M, Sfrontato N, Koerper V, Fahrner C, Schmitt D, Gantzer M, Remy-Ziller C, Brandely R, Villeval D, Rittner K, Silvestre N, Erbs P, Zitvogel L, Quéméneur E, Préville X, Marchand JB.

Oncoimmunology. 2016 Sep 9;5(10):e1220467. eCollection 2016.

9.

Polymeric Cups for Cavitation-mediated Delivery of Oncolytic Vaccinia Virus.

Myers R, Coviello C, Erbs P, Foloppe J, Rowe C, Kwan J, Crake C, Finn S, Jackson E, Balloul JM, Story C, Coussios C, Carlisle R.

Mol Ther. 2016 Sep;24(9):1627-33. doi: 10.1038/mt.2016.139. Epub 2016 Jul 4.

10.

Trial Watch-Oncolytic viruses and cancer therapy.

Pol J, Buqué A, Aranda F, Bloy N, Cremer I, Eggermont A, Erbs P, Fucikova J, Galon J, Limacher JM, Preville X, Sautès-Fridman C, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Dec 8;5(2):e1117740. eCollection 2016 Feb. Review.

11.

Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment.

Fend L, Remy-Ziller C, Foloppe J, Kempf J, Cochin S, Barraud L, Accart N, Erbs P, Fournel S, Préville X.

Oncoimmunology. 2015 Oct 6;5(2):e1080414. eCollection 2016 Feb.

12.

Oncolytic immunotherapy: The new clinical outbreak.

Fonteneau JF, Achard C, Zaupa C, Foloppe J, Erbs P.

Oncoimmunology. 2015 Aug 12;5(1):e1066961. eCollection 2016. No abstract available.

13.

Trial Watch:: Oncolytic viruses for cancer therapy.

Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Cremer I, Erbs P, Limacher JM, Preville X, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Jun 1;3:e28694. eCollection 2014. Review.

14.

Chemovirotherapy of malignant melanoma with a targeted and armed oncolytic measles virus.

Kaufmann JK, Bossow S, Grossardt C, Sawall S, Kupsch J, Erbs P, Hassel JC, von Kalle C, Enk AH, Nettelbeck DM, Ungerechts G.

J Invest Dermatol. 2013 Apr;133(4):1034-42. doi: 10.1038/jid.2012.459. Epub 2012 Dec 6.

15.

Oncolytic vaccinia virus: a silver bullet?

Lusky M, Erbs P, Foloppe J, Acres RB.

Expert Rev Vaccines. 2010 Dec;9(12):1353-6. doi: 10.1586/erv.10.137. No abstract available.

PMID:
21105770
16.

Selectivity and efficiency of late transgene expression by transcriptionally targeted oncolytic adenoviruses are dependent on the transgene insertion strategy.

Quirin C, Rohmer S, Fernández-Ulibarri I, Behr M, Hesse A, Engelhardt S, Erbs P, Enk AH, Nettelbeck DM.

Hum Gene Ther. 2011 Apr;22(4):389-404. doi: 10.1089/hum.2010.100. Epub 2011 Feb 2.

17.

Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1.

Dias JD, Liikanen I, Guse K, Foloppe J, Sloniecka M, Diaconu I, Rantanen V, Eriksson M, Hakkarainen T, Lusky M, Erbs P, Escutenaire S, Kanerva A, Pesonen S, Cerullo V, Hemminki A.

Clin Cancer Res. 2010 May 1;16(9):2540-9. doi: 10.1158/1078-0432.CCR-09-2974. Epub 2010 Apr 13.

18.

In vivo preclinical low-field MRI monitoring of tumor growth following a suicide-gene therapy in an orthotopic mice model of human glioblastoma.

Breton E, Goetz C, Kintz J, Accart N, Aubertin G, Grellier B, Erbs P, Rooke R, Constantinesco A, Choquet P.

C R Biol. 2010 Mar;333(3):220-5. doi: 10.1016/j.crvi.2009.12.012. Epub 2010 Jan 25.

PMID:
20338540
19.

Intratumoral delivery of genes: a new weapon against cancer?

Slos P, Erbs P.

Expert Rev Anticancer Ther. 2004 Aug;4(4):493-5. No abstract available.

PMID:
15270653
20.

Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer.

Céraline J, Cruchant MD, Erdmann E, Erbs P, Kurtz JE, Duclos B, Jacqmin D, Chopin D, Bergerat JP.

Int J Cancer. 2004 Jan 1;108(1):152-7.

Supplemental Content

Loading ...
Support Center